|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGHMBP2 |
Gene summary for IGHMBP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGHMBP2 | Gene ID | 3508 |
| Gene name | immunoglobulin mu DNA binding protein 2 | |
| Gene Alias | CATF1 | |
| Cytomap | 11q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P38935 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3508 | IGHMBP2 | LZE4T | Human | Esophagus | ESCC | 4.99e-20 | 4.82e-01 | 0.0811 |
| 3508 | IGHMBP2 | LZE8T | Human | Esophagus | ESCC | 3.86e-31 | 8.91e-01 | 0.067 |
| 3508 | IGHMBP2 | LZE20T | Human | Esophagus | ESCC | 3.65e-15 | 4.75e-01 | 0.0662 |
| 3508 | IGHMBP2 | LZE22D1 | Human | Esophagus | HGIN | 4.79e-02 | 1.95e-01 | 0.0595 |
| 3508 | IGHMBP2 | LZE22T | Human | Esophagus | ESCC | 1.39e-04 | 3.91e-01 | 0.068 |
| 3508 | IGHMBP2 | LZE24T | Human | Esophagus | ESCC | 3.56e-06 | 1.67e-01 | 0.0596 |
| 3508 | IGHMBP2 | P1T-E | Human | Esophagus | ESCC | 1.12e-22 | 9.87e-01 | 0.0875 |
| 3508 | IGHMBP2 | P2T-E | Human | Esophagus | ESCC | 1.04e-13 | 2.36e-01 | 0.1177 |
| 3508 | IGHMBP2 | P4T-E | Human | Esophagus | ESCC | 9.81e-10 | 2.55e-01 | 0.1323 |
| 3508 | IGHMBP2 | P5T-E | Human | Esophagus | ESCC | 5.62e-08 | 1.82e-01 | 0.1327 |
| 3508 | IGHMBP2 | P8T-E | Human | Esophagus | ESCC | 2.97e-07 | 1.38e-01 | 0.0889 |
| 3508 | IGHMBP2 | P10T-E | Human | Esophagus | ESCC | 2.10e-11 | 1.37e-01 | 0.116 |
| 3508 | IGHMBP2 | P11T-E | Human | Esophagus | ESCC | 1.18e-02 | 1.83e-01 | 0.1426 |
| 3508 | IGHMBP2 | P12T-E | Human | Esophagus | ESCC | 1.84e-10 | 1.84e-01 | 0.1122 |
| 3508 | IGHMBP2 | P15T-E | Human | Esophagus | ESCC | 2.09e-14 | 3.52e-01 | 0.1149 |
| 3508 | IGHMBP2 | P16T-E | Human | Esophagus | ESCC | 1.12e-17 | 2.60e-01 | 0.1153 |
| 3508 | IGHMBP2 | P17T-E | Human | Esophagus | ESCC | 5.59e-12 | 4.05e-01 | 0.1278 |
| 3508 | IGHMBP2 | P19T-E | Human | Esophagus | ESCC | 4.38e-04 | 4.10e-01 | 0.1662 |
| 3508 | IGHMBP2 | P20T-E | Human | Esophagus | ESCC | 1.29e-13 | 3.17e-01 | 0.1124 |
| 3508 | IGHMBP2 | P21T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.68e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00323926 | Esophagus | HGIN | DNA geometric change | 25/2587 | 90/18723 | 3.77e-04 | 5.85e-03 | 25 |
| GO:00325084 | Esophagus | HGIN | DNA duplex unwinding | 22/2587 | 84/18723 | 1.91e-03 | 2.03e-02 | 22 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
| GO:00323925 | Oral cavity | OSCC | DNA geometric change | 59/7305 | 90/18723 | 3.03e-07 | 4.63e-06 | 59 |
| GO:00325083 | Oral cavity | OSCC | DNA duplex unwinding | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
| GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGHMBP2 | SNV | Missense_Mutation | novel | c.1441N>C | p.Thr481Pro | p.T481P | P38935 | protein_coding | deleterious(0) | possibly_damaging(0.516) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs751725316 | c.1439C>G | p.Ala480Gly | p.A480G | P38935 | protein_coding | tolerated(0.16) | benign(0.158) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs751725316 | c.1439C>G | p.Ala480Gly | p.A480G | P38935 | protein_coding | tolerated(0.16) | benign(0.158) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs763336691 | c.2812N>A | p.Ala938Thr | p.A938T | P38935 | protein_coding | deleterious(0.04) | possibly_damaging(0.59) | TCGA-A7-A13G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD |
| IGHMBP2 | SNV | Missense_Mutation | novel | c.2179N>A | p.Asp727Asn | p.D727N | P38935 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs373012350 | c.608N>T | p.Ala203Val | p.A203V | P38935 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs751725316 | c.1439N>G | p.Ala480Gly | p.A480G | P38935 | protein_coding | tolerated(0.16) | benign(0.158) | TCGA-BH-A0C3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| IGHMBP2 | SNV | Missense_Mutation | rs751725316 | c.1439C>G | p.Ala480Gly | p.A480G | P38935 | protein_coding | tolerated(0.16) | benign(0.158) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs751725316 | c.1439C>G | p.Ala480Gly | p.A480G | P38935 | protein_coding | tolerated(0.16) | benign(0.158) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| IGHMBP2 | SNV | Missense_Mutation | rs751725316 | c.1439C>G | p.Ala480Gly | p.A480G | P38935 | protein_coding | tolerated(0.16) | benign(0.158) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |